Immunome (IMNM) said late Monday it intends to launch an underwritten public offering of $400 million of common stock.
The underwriters will have a 30-day option to purchase up to $60 million in additional shares.
The company said there is no guarantee the offering will be completed or what its final size or terms may be.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments